Get the Stockscreener App
9.03
1.46%
0.13
After Hours:
9.03
Amicus Therapeutics Inc stock is traded at $9.03, with a volume of 4.89M.
It is up +1.46% in the last 24 hours and up +14.59% over the past month.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$8.90
Open:
$8.9
24h Volume:
4.89M
Relative Volume:
1.02
Market Cap:
$2.78B
Revenue:
$571.16M
Net Income/Loss:
$-38.10M
P/E Ratio:
-73.71
EPS:
-0.1225
Net Cash Flow:
$-48.91M
1W Performance:
+4.15%
1M Performance:
+14.59%
6M Performance:
+17.58%
1Y Performance:
-20.93%
1-Day Range:
$8.7532
$9.17
1-Week Range:
$8.63
$9.285
52-Week Range:
$5.51
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
(609) 662-2000
Address
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
9.03 | 2.74B | 571.16M | -38.10M | -48.91M | -0.1225 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Upgrade | Needham | Hold → Buy |
| Jul-17-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-06-24 | Initiated | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| May-14-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Resumed | Goldman | Neutral |
| Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-15-21 | Upgrade | Stifel | Hold → Buy |
| Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-19-21 | Resumed | BTIG Research | Buy |
| May-27-21 | Initiated | Needham | Hold |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-02-21 | Initiated | Stifel | Hold |
| Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-19 | Initiated | H.C. Wainwright | Buy |
| Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-05-19 | Initiated | Janney | Buy |
| Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-29-18 | Initiated | Citigroup | Neutral |
| Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
| Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
| Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-18-16 | Initiated | BofA/Merrill | Buy |
| Apr-14-16 | Initiated | Robert W. Baird | Neutral |
| Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
| Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
Is Amicus Therapeutics Inc. meeting your algorithmic filter criteriaMarket Risk Report & Consistent Income Trade Recommendations - newser.com
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025 - Sahm
Using data models to predict Amicus Therapeutics Inc. stock movementShort Setup & Daily Technical Forecast Reports - newser.com
Is Amicus Therapeutics Inc. (AM6) stock undervalued at current price2025 Market Outlook & Capital Efficient Trade Techniques - newser.com
Understanding Amicus Therapeutics Inc.’s price movementRate Hike & AI Enhanced Trading Alerts - newser.com
Using RSI to spot recovery in Amicus Therapeutics Inc.Market Risk Analysis & Risk Controlled Swing Alerts - newser.com
Visual trend scoring systems applied to Amicus Therapeutics Inc.Weekly Gains Report & Weekly Setup with High ROI Potential - newser.com
Is Amicus Therapeutics Inc. stock near bottom after decline2025 Breakouts & Breakdowns & High Accuracy Swing Trade Signals - newser.com
Is Amicus Therapeutics Inc. (AM6) stock trading at attractive multiplesEarnings Summary Report & AI Driven Price Predictions - newser.com
Why Amicus Therapeutics Inc. stock is a must watch in 2025Portfolio Update Summary & Safe Capital Growth Tips - newser.com
Can Amicus Therapeutics Inc. stock maintain growth trajectoryEarnings Growth Summary & Technical Buy Zone Confirmations - newser.com
Amicus (Nasdaq: FOLD) to present at UBS and Jefferies investor conferences in Nov 2025 - Stock Titan
What earnings revisions data tells us about Amicus Therapeutics Inc.Trade Risk Summary & Technical Pattern Based Signals - newser.com
What RSI levels show for Amicus Therapeutics Inc. (AM6) stockQuarterly Portfolio Report & Growth Focused Entry Reports - newser.com
How interest rate cuts could boost Amicus Therapeutics Inc. stockEntry Point & Real-Time Market Trend Scan - newser.com
How Amicus Therapeutics Inc. (AM6) stock performs during market turbulenceWeekly Stock Recap & Low Drawdown Momentum Ideas - newser.com
Amicus Therapeutics Inc. stock chart pattern explainedWeekly Profit Report & Fast Moving Market Watchlists - newser.com
Is Amicus Therapeutics Inc AM6 a good long term investmentInsider Selling Patterns & Interactive Charts for Smarter Trading - earlytimes.in
Published on: 2025-10-31 00:48:13 - newser.com
Chart based exit strategy for Amicus Therapeutics Inc.Gap Down & Detailed Earnings Play Alerts - newser.com
Amicus Therapeutics (FOLD) to Release Earnings on Tuesday - MarketBeat
Amicus Therapeutics Inc AM6 Stock Analysis and ForecastFinancial Sector Performance & Affordable Investment Portfolio - earlytimes.in
How Amicus Therapeutics Inc. (AM6) stock moves in volatile trading sessionsTrade Analysis Summary & Free Technical Pattern Based Buy Signals - newser.com
LATAM Fabry Disease Market See Incredible Growth 2025-2032 | - openPR.com
AlphaQuest LLC Has $465,000 Stake in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Y Intercept Hong Kong Ltd Boosts Stock Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Peregrine Capital Management LLC Raises Stock Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):